Terms: = Germ cell tumor AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Clinical Outcome
29 results:
1. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
[TBL] [Abstract] [Full Text] [Related]
2. Modifier Role of Common
Skalniak A; Trofimiuk-Müldner M; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769224
[No Abstract] [Full Text] [Related]
3. Cystic ovarian teratoma as a novel tumor and growth hormone deficiency as a new condition presenting in Multiple Endocrine Neoplasia type 2B: Case reports and review of the literature.
Pomahacova R; Paterova P; Nykodymova E; Vaclavikova E; Sykorova P; Personova K; Katra R; Subrt I; Sykora J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):105-111. PubMed ID: 34446941
[TBL] [Abstract] [Full Text] [Related]
4. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
[TBL] [Abstract] [Full Text] [Related]
5. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.
Moura MM; Cabrera RA; Esteves S; Cavaco BM; Soares P; Leite V
J Endocrinol Invest; 2021 Sep; 44(9):1837-1846. PubMed ID: 33575974
[TBL] [Abstract] [Full Text] [Related]
6. ret Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with ret Somatic Mutations and High Allelic Frequency.
Ramone T; Mulè C; Ciampi R; Bottici V; Cappagli V; Prete A; Matrone A; Piaggi P; Torregrossa L; Basolo F; Elisei R; Romei C
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33383911
[TBL] [Abstract] [Full Text] [Related]
7. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
[TBL] [Abstract] [Full Text] [Related]
8. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract] [Full Text] [Related]
9. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
[TBL] [Abstract] [Full Text] [Related]
10. ATF4 Targets ret for Degradation and Is a Candidate tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract] [Full Text] [Related]
11. Surgical Treatment of Medullary Thyroid Cancer.
Machens A; Dralle H
Recent Results Cancer Res; 2015; 204():187-205. PubMed ID: 26494390
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract] [Full Text] [Related]
13. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Wiesner T; He J; Yelensky R; Esteve-Puig R; Botton T; Yeh I; Lipson D; Otto G; Brennan K; Murali R; Garrido M; Miller VA; Ross JS; Berger MF; Sparatta A; Palmedo G; Cerroni L; Busam KJ; Kutzner H; Cronin MT; Stephens PJ; Bastian BC
Nat Commun; 2014; 5():3116. PubMed ID: 24445538
[TBL] [Abstract] [Full Text] [Related]
14. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract] [Full Text] [Related]
15. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract] [Full Text] [Related]
16. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005.
Grozinsky-Glasberg S; Benbassat CA; Tsvetov G; Feinmesser R; Peretz H; Shimon I; Lapidot M
Thyroid; 2007 Jun; 17(6):549-56. PubMed ID: 17614776
[TBL] [Abstract] [Full Text] [Related]
17. [ret and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
[TBL] [Abstract] [Full Text] [Related]
18. Molecular advances in medullary thyroid cancer diagnostics.
Hubner RA; Houlston RS
Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
[TBL] [Abstract] [Full Text] [Related]
19. clinical case seminar: in vivo and in vitro characterization of a novel germline ret mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
[TBL] [Abstract] [Full Text] [Related]
20. A study of histopathological features of medullary carcinoma of the thyroid: cases from a single institute in India.
Desai SS; Sarkar S; Borges AM
Indian J Cancer; 2005; 42(1):25-9. PubMed ID: 15805688
[TBL] [Abstract] [Full Text] [Related]
[Next]
